Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Clinical Study to Evaluate the Safety and Initial Efficacy of Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) in the Treatment of Relapsed or Refractory t(8; 21) AML

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06499025
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:23.755755+00:00
Published At
2025-08-28T00:00:00+00:00
Record Updated At
2025-08-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["AML", "t(8;21)", "Neoantigen"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-08-28"
protocolSection.identificationModule.nctId
"NCT06499025"
protocolSection.identificationModule.officialTitle
"A Clinical Study to Evaluate the Safety and Initial Efficacy of Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) in the Treatment of Relapsed or Refractory t(8; 21) AML"
protocolSection.statusModule.overallStatus
"ENROLLING_BY_INVITATION"
protocolSection.designModule.phases
["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • AML (protocolSection.conditionsModule.conditions)
  • t(8;21) (protocolSection.conditionsModule.conditions)
  • Neoantigen (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.